Journal of Family Medicine and Primary Care

REVIEW ARTICLE
Year
: 2019  |  Volume : 8  |  Issue : 6  |  Page : 1855--1862

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure


Akshyaya Pradhan, Shweta Vohra, Pravesh Vishwakarma, Rishi Sethi 
 Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India

Correspondence Address:
Dr. Akshyaya Pradhan
Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh - 226 003
India

SGLT-2 inhibitors are a novel class of anti-diabetic agents which act by inhibiting glucose reabsorption in proximal convoluted tubules of kidney. Apart from maintaining glucose homeostasis they exert a number of positive effects on the cardiovascular system like weight loss, decreasing blood pressure, preserving renal function, reducing triglycerides, natriuresis and improving endothelial dysfunction. In large clinical trials, all the three prototype agents – Empaglifozin, Canaglifozin and dapaglifozin have shown reductions in major adverse cardiovascular events including cardiovascular deaths, non fatal MI, stroke and heart failure (HF) hospitalizations. The reduction in heart failure hospitalization is a surprising finding and trials of these drug are now underway for HF also. More surprising is the fact that the benefits are comparable or even better that achieved by recently approved novel drugs for HF. In this review, we briefly discuss the pathophysiology of HF in diabetes, describe the prototype SGLT-2 molecules available, their data from large cardiovascular outcome trials till date and their role in current practice of diabetes management.


How to cite this article:
Pradhan A, Vohra S, Vishwakarma P, Sethi R. Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure.J Family Med Prim Care 2019;8:1855-1862


How to cite this URL:
Pradhan A, Vohra S, Vishwakarma P, Sethi R. Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure. J Family Med Prim Care [serial online] 2019 [cited 2019 Aug 20 ];8:1855-1862
Available from: http://www.jfmpc.com/article.asp?issn=2249-4863;year=2019;volume=8;issue=6;spage=1855;epage=1862;aulast=Pradhan;type=0